Sagimet Biosciences Inc (SGMT)
4.32
-0.13
(-2.92%)
USD |
NASDAQ |
May 03, 16:00
4.32
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Cash from Operations (Quarterly): -7.083M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -7.083M |
| September 30, 2023 | -3.879M |
| June 30, 2023 | -5.72M |
| March 31, 2023 | -7.084M |
| December 31, 2022 | -7.453M |
| Date | Value |
|---|---|
| September 30, 2022 | -6.234M |
| June 30, 2022 | -6.138M |
| March 31, 2022 | -4.665M |
| March 31, 2021 | -4.903M |
| March 31, 2020 | -2.598M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-7.453M
Minimum
Dec 2022
-2.598M
Maximum
Mar 2020
-5.576M
Average
-5.929M
Median
Cash from Operations (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -79.93M |
| 89bio Inc | -34.29M |
| Viking Therapeutics Inc | -6.134M |
| Akero Therapeutics Inc | -48.63M |
| Arrowhead Pharmaceuticals Inc | -117.84M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -19.62M |
| Free Cash Flow | -23.77M |
| Free Cash Flow Per Share (Quarterly) | -0.3094 |
| Free Cash Flow Yield | -25.76% |